Magle Chemoswed Holding AB Stock price

Equities

MAGLE

SE0014401014

Pharmaceuticals

Market Closed - Nasdaq Stockholm 07:32:03 2024-03-28 am EDT 5-day change 1st Jan Change
32.2 SEK +3.21% Intraday chart for Magle Chemoswed Holding AB +11.81% +27.78%
Sales 2023 170M 15.91M Sales 2024 * 189M 17.68M Capitalization 348M 32.47M
Net income 2023 12M 1.12M Net income 2024 * 24M 2.24M EV / Sales 2023 1.86 x
Net Debt 2023 45.42M 4.24M Net Debt 2024 * 42.5M 3.97M EV / Sales 2024 * 2.06 x
P/E ratio 2023
22.3 x
P/E ratio 2024 *
14.6 x
Employees 75
Yield 2023 *
-
Yield 2024 *
-
Free-Float 21.39%
More Fundamentals * Assessed data
Dynamic Chart
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI
Magle Chemoswed Holding AB Proposes Dividend for the Fiscal Year 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Magle Group Announces Positive Results from Post-Market Clinical Follow-Up of SmartPAN CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait CI
Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina CI
Magle Chemoswed Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Magle Appoints New Chief Marketing/Innovation Officer MT
More news
1 day+3.21%
1 week+11.81%
Current month+27.78%
1 month+27.78%
3 months+25.78%
6 months-4.17%
Current year+27.78%
More quotes
1 week
29.20
Extreme 29.2
32.20
1 month
24.40
Extreme 24.4
35.00
Current year
24.40
Extreme 24.4
35.00
1 year
21.40
Extreme 21.4
38.00
3 years
20.00
Extreme 20
44.50
5 years
19.60
Extreme 19.602
49.00
10 years
19.60
Extreme 19.602
49.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 14-12-31
Director of Finance/CFO - 20-06-30
Chief Operating Officer 48 98-12-31
Members of the board TitleAgeSince
Director/Board Member 78 15-12-31
Director/Board Member 80 15-12-31
Director/Board Member 44 19-12-31
More insiders
Date Price Change Volume
24-03-28 32.2 +3.21% 107
24-03-27 31.2 +4.00% 1,722
24-03-26 30 +0.67% 1,020
24-03-25 29.8 +2.05% 5,905
24-03-22 29.2 +1.39% 4,277

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:32 am EDT

More quotes
Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
Calendar
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Magle Chemoswed Holding AB - Nasdaq Stockholm